JV moves Immucor closer to direct presence in Japan:
This article was originally published in Clinica
Immucor is to take a majority interest in a new joint venture with the Japanese distributor of its blood transfusion diagnostics, Kainos Laboratories. It will pay $3.7m for a 51% initial stake in the venture, which will assume responsibility for Immucor's distribution in Japan. Eventually, the Norcross, Georgia-based company expects to buy the business outright and assume direct distribution of its products in Japan, the third-largest transfusion diagnostics market after the US and Europe.
You may also be interested in...
AMAG outlines plans for retrospective real-world evidence studies, and possibly a new placebo-controlled trial with a primary endpoint of preterm birth <32 weeks, in a filing opposing the Center for Drug Evaluation and Research’s proposal to withdraw the drug.
The leading Korean pharma firm’s oral, third-generation EGFR-TKI is approved in the country, providing a new option for patients with advanced NSCLC and increasing hopes for global approvals given an ongoing global Phase III combination trial led by partner J&J.
DePuy Synthes expects its Velys robotic-assisted system to be cost-effective, easy-to-use and to be well-suited for use in ambulatory surgery centers.